All news

Does Growth Drug Sales Change The Bull Case For Bristol Myers Squibb Stock?

Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash

Bristol-Myers Squibb's third-quarter 2026 results show its growth drug portfolio is generating significant revenue, helping to offset pressure from patent expirations on older drugs. While revenue increased, net income remained relatively flat, shifting investor focus to margins and product mix. Analysts forecast a modest revenue decline and an earnings decrease by 2029, with some bullish views highlighting profit margin potential.

Read original source

BMY company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.